Please ensure Javascript is enabled for purposes of website accessibility

Why Nano-X Stock Dropped 9%, Bounced Back 25%, and Is Still Up 5.5% Today

By Rich Smith – Sep 16, 2020 at 12:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock yo-yos as investors struggle to decide whom to believe.

What happened

Shares of Nano-X Imaging (NNOX -6.92%) had rocketed 250% from their IPO price through the close of trading last week. But the shares tumbled 23% yesterday after Citron Research issued a savage short report on the company, accusing the Israeli X-ray machine maker of being little more than "a stock promotion" and predicting the shares will go to $0.

Today, the selling-off started again early, as Nano-X stock fell a further 9%, then reversed course, recovered all their losses, jumped 16% higher, and then finally gave back some of their gains. As of 11:45 a.m. EDT, these yo-yoing stock movements have left Nano-X shares trading 5.5% above yesterday's close.  


Doctor shows patient a chest x-ray

Image source: Getty Images.

So what

No mystery here: Nano-X stock fell this morning because it takes time for a stock to reverse course once it's started the kind of downward momentum we saw yesterday. But the stock did rebound eventually as investors learned that Nano-X management is disputing Citron's findings.

In a terse rebuttal this morning, Nano-X blamed Citron exclusively for "the unusual trading activities in its ordinary shares" yesterday (i.e. there was no other bad news happening at the company, just the report itself). And Nano-X went a bit further, arguing that Citron's report "contains factual errors and misleading speculations" and is "completely without merit."  

Now what

Granted, as rebuttals go, this one was a bit long on absolutes and a bit short on specifics, but Nano-X management promised to "provide additional information on the allegations" after "carefully reviewing the report."

Where the stock goes from here will largely depend on whether Nano-X can put together a reasoned explanation for why Citron is wrong. It probably wouldn't hurt, either, if Nano-X could unveil a functioning CT scanner -- like the one Citron says it doesn't have.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.